Nabriva clears first big hurdle in proof-of-concept study


Vienna – Nabriva Therapeutics AG, an Austrian specialist for the development of novel antibiotics, has achieved proof-of-concept for its first product in a clinical Phase II study. Called BC-3781, the compound is used to treat acute bacterial skin and skin structure infections. It is the first substance in a new class of system­ically available pleuromutilin anti­biotics for the treatment of serious skin infections and pneumonia. BC-3781 is being developed for both oral and intravenous formulations. In 207 patients recruited in 23 centers in the US, the study compared two doses of BC-3781 with Vancomycin, the gold standard for drug resistant Gram-positive bacterial skin infections. Nabriva was able to show non-inferiority compared to Vancomycin. Patients receiving BC-3781 in two different dose regimens (100mg and 150mg) showed a similar treatment success compared to Vancomycin. Nabriva is the successor of the Antibiotics Research Institute (ABRI), a former affiliate of Sandoz AG. The decision to spin-out antibiotics research in 2006 followed a strategic re-orientation of the Sandoz unit within the mother company Novartis. Nabriva’s shareholders include a big-name investor syndicate made up of Phase4 Ventures, HBM, The Wellcome Trust, GLSV and the Novartis Venture Fund.



Breast cancer patients who receive radiation therapy often suffer from inflammation linked to the treatment. Austrian Apeiron Biologics AG is now developing a topical superoxide dismutase treatment (APN201) to try to help these...



The Paracelsus Private Medical University (PMU) in Salzburg is to build a new research center for spinal cord injuries. The €70m construction tab will be picked up by Dietrich Mateschitz, the owner of Red Bull. Other partners in...



Vienna – Two big investors have poured €25m into Austrian vaccine specialist Affiris AG. Venture fund Santo VC – the investment vehicle of German biotech investors Thomas and Andreas Strüngmann – donated €20m, while the German...



Vienna – In Affiris they trust – as a proof of their faith, two big investors poured €25 million into the Austrian developer of a possible Alzheimer drug. Venture fonds Santo VC, the investment vehicle of the German billionaires...



Innsbruck – Austrian specialist for so-called ugimeres, Ugichem GmbH, has landed fresh funding. Along with V+ GmbH and the Austrian Research Promotion Agency, Swiss private investors invested about EUR2m to develop the first...



Innsbruck – An Austrian physician has been fined EUR4,500 in a case involving a controversial stem cell therapy for incontinence. In early August, an Innsbruck Regional Court adjudged Hannes Strasser, who developed the method, at...



Vienna – Nabriva Therapeutics AG, an Austrian specialist for the development of novel antibiotics, has achieved proof-of-concept for its first product in a clinical Phase II study. Called BC-3781, the compound is used to treat...



Vienna - f-star, an antibody specialist, today announced the closing of aEUR 15 Million financing. The investment was led by SR One, the corporate venture capital arm of GlaxoSmithKline. All of f-star’s existing investors, Atlas...



Vienna – Apeiron Biologics has entered into an exclusive option with the Cleveland Clinic to license a number of novel compounds that are currently in development there. The drug candidates are designed to fight cancer by...

Displaying results 1 to 10 out of 116

1-10 Next >

© 2007-2015 BIOCOM


LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week



All Events


Frankfurt am Main (DE)


Stock list

All quotes


  • EVOTEC4.06 EUR4.10%
  • VITA 345.72 EUR3.06%
  • SARTORIUS165.00 EUR2.77%


  • CYTOS0.65 CHF-4.41%
  • WILEX4.06 EUR-4.02%
  • CO.DON2.80 EUR-3.78%


  • 4SC4.61 EUR260.2%
  • SYNGENTA422.10 CHF29.1%
  • WILEX4.06 EUR19.4%


  • CYTOS0.65 CHF-40.9%
  • MEDIGENE9.02 EUR-28.9%
  • BIOTEST76.17 EUR-22.6%


  • WILEX4.06 EUR401.2%
  • CYTOS0.65 CHF364.3%
  • 4SC4.61 EUR319.1%


  • MOLOGEN4.89 EUR-54.7%
  • BIOFRONTERA2.30 EUR-24.1%
  • CO.DON2.80 EUR-23.7%

No liability assumed, Date: 22.05.2015

Current issue

All issues